ST
ACAD icon

Spot Trading’s Acadia Pharmaceuticals ACAD Stock Holding History

Spot Trading’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-7,701
Closed -$204K – 2720
2016
Q3 		$245K Buy
+7,701
New +$261K 0.01% 1959
2016
Q2 		– Sell
-1,270
Closed -$36K – 3261
2016
Q1 		$36K Buy
1,270
+1,250
+6,250% +$27.3K ﹤0.01% 2898
2015
Q4 		$1K Sell
20
-2,799
-99% -$98.6K ﹤0.01% 3505
2015
Q3 		$93K Sell
2,819
-7,564
-73% -$315K ﹤0.01% 3082
2015
Q2 		$435K Buy
10,383
+10,233
+6,822% +$396K ﹤0.01% 2209
2015
Q1 		$5K Sell
150
-2,736
-95% -$94K ﹤0.01% 3652
2014
Q4 		$92K Buy
2,886
+2,692
+1,388% +$76.3K ﹤0.01% 3264
2014
Q3 		$5K Sell
194
-1,806
-90% -$42.2K ﹤0.01% 4124
2014
Q2 		$45K Sell
2,000
-5
-0.2% -$104 ﹤0.01% 3952
2014
Q1 		$49K Sell
2,005
-6,178
-75% -$156K ﹤0.01% 3641
2013
Q4 		$204K Sell
8,183
-244
-3% -$5.76K ﹤0.01% 3011
2013
Q3 		$231K Sell
8,427
-19,830
-70% -$415K ﹤0.01% 2914
2013
Q2 		$513K Buy
+28,257
New +$389K ﹤0.01% 2421

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Spot Trading's ACAD Position: Q4 2016 in Review

Spot Trading sold out of Acadia Pharmaceuticals (ACAD) in Q4 2016, closing a stake of 7,701 shares — an estimated $204K sold.

Spot Trading first reported a position in ACAD in Q2 2013 and held it in 13 quarters. The position peaked at $513K in Q2 2013. 225 funds tracked by Wall St. Rank hold ACAD as of Q4 2016.

  • Spot Trading reported no remaining Acadia Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Spot Trading sold 7,701 Acadia Pharmaceuticals shares in Q4 2016, an estimated $204K.
  • Spot Trading first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • Spot Trading's Acadia Pharmaceuticals position peaked at $513K in Q2 2013.
  • 225 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2016.

Based on Spot Trading's 13F filing for Q4 2016, filed 7 Feb 2017.